Treatment with bevacizumab for ocular vascular lesions

Treatment with bevacizumab for ocular vascular lesions - Treatment with bevacizumab for ocular vascular lesions

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020916

Enrollment

1000

Registered

2016-02-07

Start date

2016-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular vascular lesions

Interventions

ocular injection of bevacizumab (1mg/0.04ml/injection, if needed, injection can be added after 1 month of interval)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ocular vascualr lesions

Exclusion criteria

Exclusion criteria: Those who cannot understand the impact of the study

Design outcomes

Primary

Measure	Time frame
Ocular findings including best-corrected visual acuity and fundus findings 6 months after initial injection	—

Countries

Japan

Contacts

Public ContactYoko Ozawa

Keio University, School of Medicine Department of Ophthalmology

ozawa@a5.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026